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Key messages
 ► Developers of new high-risk medical devices should 
plan how they will produce evidence from the ear-
liest stage, for all the stakeholders who will need it. 
The audiences include regulators, health technolo-
gy assessors, policy-makers, payers, clinicians and 
patients.
 ► Planning studies and data collection for the total 
product life cycle of a new device increases the effi-
ciency and reduces the cost of evidence generation. 
Randomized controlled trials remain necessary for 
novel devices and indications, but other methods 
also exist to bolster an early evidence base.
 ► Regulators increasingly require real-word evidence 
in the longer term, especially for implanted devices. 
Well-planned registers, data linkage and unique de-
vice identifiers will facilitate this.
IntroduCtIon
Evidence is the currency that medical device 
developers create from the data of clinical 
and other studies to support adoption of 
their products into healthcare. The evidence 
is used by a range of stakeholders (box 1) in 
determining whether a new device will be 
marketed, paid for by health insurance and 
adopted. Regulators need evidence on safety, 
performance and efficacy. Health technology 
assessment (HTA) organizations, payers and 
policy-makers are interested in clinical and 
cost-effectiveness. Clinicians and patients 
want to know about comparative effective-
ness, ease of use, durability, and risks in the 
short and long term.
Much has been written about the chal-
lenges facing medical device developers 
in producing all the evidence needed for a 
new device to become widely used in patient 
care.1–7 These challenges are especially diffi-
cult for small companies and developers. 
Trials are vexed by learning curves and rapid 
iterations of device design, adding to the diffi-
culties of choosing appropriate comparators 
and outcomes.2 8 9 Speed of evidence genera-
tion matters because it is a costly process. The 
life cycle of most medical devices is short, so 
delays in getting the device to market will 
reduce the duration of profitable marketing 
and may make it non-viable. If a new device 
offers real advantages to patients, there are 
public health reasons for enabling patient 
access with minimal delay.
This article explores the evidence needed to 
satisfy the range of stakeholders. It describes 
changes being introduced by regulators 
in the evidence they require for high-risk 
devices. While challenging, efficient genera-
tion of evidence can be achievable through 
good planning early in the product develop-
ment cycle.
Evidence required for regulation
Changes are afoot in device regulation 
around the world, leading to uncertainties 
about what evidence will be needed for new 
high-risk devices, with increasing emphasis 
on long-term, real-world data.10–13 It is now 
recognized that the findings of randomized 
controlled trials (RCTs) may not predict 
how new devices will perform in everyday 
use.3 14 In addition, the pace of device iter-
ation often means that the findings of long-
term RCTs are no longer relevant by the time 
they become available. RCTs remain neces-
sary for devices which are conceptually novel 
or being used for radically new indications; 
however, a variety of statistical and validation 
methods are now available for enhancing the 
usefulness of non-randomized studies such 
as propensity scoring and linked evidence 
approaches.3 15 The increased recognition of 
RCTs’ shortcomings and the additional value 
of real-world data collection has led to the 
shift of balance in regulatory decisions toward 
the latter, based on “conditional approval” 
and “Coverage with Evidence Development 
(CED)”.
Data obtained throughout the total 
product life cycle are particularly important 
for high-risk and implanted devices. Regula-
tors are increasing their focus on collection 
and review of data after market approval.16 17 
This shift is taking place around the world, 
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Box 1 range of stakeholders, for whom a spectrum of 
evidence is needed
 ► Regulators (eg, Food and Drug Administration (FDA) in the USA; 
Medicines and Healthcare products Regulatory Agency (MHRA) in 
the UK).
 ► Health Technology Assessment organizations.
 ► Policy-makers.
 ► Payers (commissioners, insurance companies, Centers for Medicare 
& Medicaid Services (CMS)).
 ► Clinicians.
 ► Hospital procurement managers.
 ► Patients and caregivers.
supported by guidance from the International Medical 
Device Regulators Forum (IMDRF) aimed at harmoni-
zation of approach.18 Japan and Saudi Arabia have both 
incorporated harmonized material into their medical 
device regulations.19 20 China’s regulatory framework has 
evolved dramatically over the last 10 years and India’s new 
Medical Device Rules came into force in January 2018.21–24
Evidence required for HtA and reimbursement decisions
HTA and reimbursement decisions have tradition-
ally presupposed that regulators are fully satisfied with 
evidence on safety and efficacy. However, by necessity, 
regulatory decisions typically are made when evidence is 
incomplete: much of the evidence on use of devices in 
different patient populations or by different clinicians, 
and long-term effectiveness and safety can only be gener-
ated by “real-world” practice after market approval by 
regulators. To capture this evidence, systems are needed 
that enable clinical care information to reach the status 
of valid scientific evidence fit for regulatory, HTA and 
health-policy decision-making.25
HTA agencies and payers are interested in value for 
patients and healthcare systems, based on evidence about 
health outcomes, rather than efficacy alone. In general, 
HTA organizations evaluate comparative effectiveness to 
determine whether the new technology performs better 
than what is in current use. In addition, many of them 
also use evidence on health utilities to calculate a cost per 
QALY (quality-adjusted life year).26
Evidence generation for health economic evaluation 
is often neglected by product developers, but through 
discussion with clinicians, health economists and most 
importantly HTA organizations, they should be able to 
identify key information, normally health-related quality 
of life data, required for health economic modelling, 
around the time of product launch.4 Thereafter, resource 
utilization data will be needed about replacement of the 
device or component parts, or other necessary interven-
tions, to inform economic modeling.
Finally, healthcare professionals, hospitals/providers 
and patients will want to know whether the device is 
safe, whether it works better than the alternatives, how 
much it costs and whether it is convenient to use. Clini-
cians are particularly interested in knowing how a device 
is performing in the hands of colleagues, and they may 
contribute their own data to trials and registries.
Long-term data collection as a key challenge
Collection of data in the long term remains a challenge 
but is becoming more routine, with increasing potential 
to link and merge electronic data from different sources, 
such as device and disease registries, routinely collected 
healthcare data, medical insurance claims and unique 
device identifiers (UDIs). If the main potential benefits 
of a new device will be realized only in the long term (or 
if there are potential long-term risks), then it is important 
to identify the best short-term or surrogate outcomes to 
support early post-market adoption of the device. It is 
also important to consider how long-term outcomes will 
be gathered: is it necessary to establish a new, specific 
registry or will early liaison with an established registry be 
a better option?
Continuous acquisition of long-term data for high-risk 
devices (such as implants) and high-cost technologies 
(such as new imaging machines) is best planned from the 
earliest stage, collecting information about all patients in 
whom the device has been used.27 28 Creating linkages of 
device-specific data to other datasets (eg, national health-
care and population statistics, or administrative claims 
data), which may be used in the long term for investi-
gating possible outcomes, will become increasingly valu-
able. Identifying a core set of data elements (each with 
agreed definitions) and plans for linkage should be speci-
fied from the outset, when describing strategies for gener-
ating long-term evidence. Examples of systems which 
aim to collect data on devices that can be used by regu-
lators are the VISION initiative (http:// mdepinet. org/ 
vision- crn/ initiative) in the USA, which is the National 
Evaluation System for Health Technology vascular device 
demonstration project, and Beyond Compliance initia-
tive in orthopedics in the UK.25 29 30
UDIs are now being attached to all high-risk devices: 
these will greatly potentiate the capacity to track indi-
vidual devices, provide information on different versions 
of each device and collate information about devices 
of a similar type. Linkage of UDIs to electronic patient 
records, including administrative claims, will expand the 
potential for a range of other links and for subsequent 
analyses. The extent to which this can be achieved will 
depend on the organization of health systems and atti-
tudes to data access in different countries. In the UK, data 
linkage studies have been used on very large datasets such 
as the Clinical Practice Research Datalink which contains 
primary care data from several million patients.31 32 
Sharing data internationally could provide even larger 
datasets, which would generate safety signals more rapidly 
than in the past. Efforts are being made to achieve inter-
national collaborations, but they need careful attention 
to different countries’ data protection laws.33 34
Many useful device, procedure and disease regis-
tries exist, most held by professional medical societies 
and national agencies.35 36 The datasets held by device 
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Box 2 types of value proposition for medical devices
 ► The device gives a return on investment by reducing overall costs 
of care.
 ► The device offers increased benefits for patients but at increased 
cost.
companies have great potential, provided there are clear 
arrangements for governance and transparency.37 As part 
of EUnetHTA Joint Action 3, REQueST tool, a quality 
standards tool for registries, has been developed and vali-
dated by HTA agencies.38 The IMDRF has also published 
useful material.39 40
Value propositions for different countries
Data from well-planned studies on efficacy, performance, 
safety and clinical effectiveness are likely to be relevant 
universally. However, clinical practice differs between 
countries and overall costs of care often vary consider-
ably.41 Device use may vary by indication, involve different 
types and numbers of staff, or divergent practices (eg, 
visits to hospital and follow-up). These differences mean 
that resource use and cost data from other countries 
may be inapplicable—for example, in the National Insti-
tute for Health and Care Excellence (NICE) evaluation 
of TURIS (TransUrethral Resection of the prostate In 
Saline).42
Quality-of-life data, required to calculate incremental 
benefit to patients, are normally generalisable but where 
a device’s value proposition (box 2) is a return on invest-
ment rather than incremental benefit at higher cost, its 
impact on pathways, clinical practices, staffing and reim-
bursement may all affect its value case. HTA agencies 
therefore often use their own country’s standardized data 
for estimating the likely cost of introducing a new device, 
compared with current practice.43 A limited cost study in 
the relevant country may be a better strategy than using 
more robust data already available from another country. 
Plans for creating a good value proposition should be 
considered early during product development and 
discussed with a health economist.
Early engagement to plan a strategy for evidence generation
Early planning is key to producing evidence in the most 
efficient and economical way. The input from regulators, 
HTA experts and payers is crucial in designing studies for 
market approval, insurance or health service coverage, 
and adoption of the device. Box 2 summarizes the main 
types of value propositions for HTA and reimbursement 
decisions. Listening to advice from patients and clinicians 
(a broad range of knowledgeable people rather than 
enthusiasts) is critical in planning, especially when a new 
device is addressing an unmet need or providing advan-
tages for patients over devices in current use.
There is an inherent tendency for developers to avoid 
meeting with regulators early in the device development 
process, but this is not a winning strategy. In the USA, 
the FDA/Center for Devices and Radiological Health 
(CDRH) has developed the Pre-submission Program 
that supports early meetings to discuss innovative study 
designs and to guide developers in evidence generation 
for marketing approval.44 For example, FDA may suggest 
a limited early feasibility study to accelerate plans for 
initial clinical evidence—often a funding milestone.45 
Early, frequent meetings with FDA can help to design 
lean, non-clinical testing plans (ie, “just-in-time-testing”), 
while deferring other testing until device design is final-
ized. When a pivotal clinical trial is planned, the FDA/
CDRH Payer Communication Task Force (PCTF) has 
developed a process to engage the payer/HTA commu-
nity for advice on their evidentiary needs or potentially 
for Parallel Review with CMS.46 47
Early advice from a range of stakeholders will enable a 
strategy which avoids the pitfall of generating evidence 
for regulators, then HTA, then other audiences, in 
sequence, as each appears on the horizon. The strategy 
should include a clear plan for continuous collection 
of evidence in the long term. Ideally, for high-risk or 
implantable devices, comprehensive data collection 
should be started from the first use in man—either by 
liaison with an existing registry or by establishing a new 
one.27 28 This can be a demanding task, but early effort 
will pay dividends in the long term. Any registry should 
include a clear record of the times when a device under-
goes modifications, including UDI information that can 
differentiate between versions of the device.
Worldwide collaborative initiatives by regulators and payers 
to facilitate evidence generation
Recognising the importance of good early planning 
and the uncertainties that developers and manufac-
turers of devices can face, regulators and HTA agencies 
now offer processes for providing advice and assistance. 
In the USA, FDA/CDRH has developed the PCTF inte-
grated with CMS/Coverage and Analysis Group (CAG) 
to offer a Parallel Review program, which includes 
pre-clinical trial design advice from CMS and simul-
taneous review of the trial data.46 47 The PCTF initia-
tives include options for pre-trial communication with 
private payers and HTA agencies in the USA and the UK 
(NICE). NICE has its own Scientific Advice program, 
which offers a META tool to guide companies on their 
plans for clinical trials and data collection.48 The MaRS 
EXCITE initiative in Canada aims at introducing “inno-
vative health companies” to relevant stakeholders.49
There will be some differences in the evidence 
required in different countries, arising primarily from 
statutory requirements, but the similarities in the data 
needed generally exceed these national variations.
For novel devices that require use of new surgical 
procedures, and for novel surgical procedures devel-
oped to support the use of devices, the IDEAL concept 
provides a framework for the kind of evidence needed 
at each stage of development.28 36 50
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ConCLusIon
Generating evidence for regulation and for value assess-
ment of new medical devices are often thought of as 
separate activities, but for the most efficient and least 
expensive strategy, developers need to adopt an inte-
grated approach to evidence generation across the 
total product life cycle, rather than a series of ad hoc 
studies to address sequential needs. This evidence 
generation should address the whole spectrum of stake-
holders: early communication with them will guide the 
design of studies to generate the most useful evidence 
in the most efficient way. All stakeholders have some 
responsibility for collecting long-term data, and this is 
another reason for involving them early. This approach 
will contribute to innovation by reducing the time and 
cost of generating pre-market data, while managing 
risk through structured collection of information once 
devices are in use. The efforts involved in planning 
long-term data collection may be considerable, but 
they are outweighed by the potential rewards of earlier 
patient access, capacity to respond to subsequent regu-
latory or HTA challenges, and an enhanced reputation 
for corporate excellence.
Funding The authors have not declared a specific grant for this research from any 
funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Patient consent for publication Not required.
Provenance and peer review Commissioned; internally peer reviewed.
open access This is an open access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non-commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the use 
is non-commercial. See: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
rEFErEnCEs
 1. Hulstaert F, Neyt M, Vinck I, et al. Pre-market clinical evaluations of 
innovative high-risk medical devices in Europe. Int J Technol Assess 
Health Care 2012;28:278–84.
 2. Gelijns AC, Russo MJ, Hong KN, et al. Dynamics of device 
innovation: implications for assessing value. Int J Technol Assess 
Health Care 2013;29:365–73.
 3. Bernard A, Vaneau M, Fournel I, et al. Methodological choices for the 
clinical development of medical devices. MDER 2014;7:325–34.
 4. Craig JA, Carr L, Hutton J, et al. A review of the economic tools for 
assessing new medical devices. Appl Health Econ Health Policy 
2015;13:15–27.
 5. Holmes DR, Califf R, Farb A, et al. Overcoming the challenges of 
conducting early feasibility studies of medical devices in the United 
States. J Am Coll Cardiol 2016;68:1908–15.
 6. Campbell B, Dobson L, Higgins J, et al. A new health technology 
assessment system for devices: the first five years. Int J Technol 
Assess Health Care 2017;33:19–24.
 7. Tarricone R, Torbica A, Drummond M. Challenges in the assessment 
of medical devices: the MEDTECHTA project. Health Econ 2017;26 
Suppl 1:5–12.
 8. Ramsay CR, Grant AM, Wallace SA, et al. Assessment of the learning 
curve in health technologies a systematic review. Int J Technol 
Assess Health Care 2000;16:1095–108.
 9. Samuel AM, Rathi VK, Grauer JN, et al. How do orthopaedic devices 
change after their initial FDA Premarket approval? Clin Orthop Relat 
Res 2016;474:1053–68.
 10. Kaushik D, Rai S, Dureja H, et al. Regulatory perspectives on 
medical device approval in global jurisdictions. J Generic Med 
2013;10:159–71.
 11. Regulation. (EU) 2017;745.
 12. Regulation. (EU) 2017;746.
 13. Clinical evaluation: a guide for manufacturers and notified bodies 
under directives 93/42/EEC and 90/385/EEC. Meddev 2.7.1 v42016.
 14. Faris O, Shuren J. An FDA viewpoint on unique considerations for 
medical-device clinical trials. N Engl J Med 2017;376:1350–7.
 15. Campbell G, Yue LQ. Statistical innovations in the medical device 
world sparked by the FDA. J Biopharm Stat 2016;26:3–16.
 16. US Food & Drug Administration. Use of real-world evidence to 
support regulatory decision-making for medical devices, 2017. 
Available: https://www. fda. gov/ downloads/ medicaldevices/ devi cere 
gula tion andg uidance/ guidancedocuments/ ucm3479248. pdf
 17. Center for Devices and Radiological Health. Balancing premarket 
and postmarket data collection for devices subject to premarket 
approval, 2017. Available: https://www. fda. gov/ downloads/ 
medicaldevices/ devi cere gula tion andg uidance/ guidancedocuments/ 
ucm393994. pdf
 18. IMDRF. International medical device regulators forum. Available: 
http://www. imdrf. org/
 19. ‘Act on Securing Quality Efficacy and Safety of Pharmaceuticals, 
Medical Devices, Regenerative and Cellular Therapy Products, Gene 
Therapy Products, and Cosmetics’ November 25; 2014.
 20. Medical Devices Interim Regulation 27.12.2008—Saudi Regulations; 
2008.
 21. Kramer DB, Tan YT, Sato C, et al. Ensuring medical device 
effectiveness and safety: a cross-national comparison of approaches 
to regulation. Food Drug Law J 2014;69:1-23, i.
 22. Decree of the State Council of People’s Republic of China No. 650; 
2014.
 23. CFDA. Technical guidance on clinical evaluation of medical devices—
class II and III; 2015.
 24. INDIA—Medical Device Rules, 2017, Gazette of India: Extraordinary 
[Part II—Section 3(i)] 2017.
 25. FDA. National Evaluation System for Health Technology (NEST). 
Available: https://www. fda. gov/ aboutfda/ centersoffices/ offi ceof medi 
calp rodu ctsa ndto bacco/ cdrh/ cdrhreports/ ucm301912. htm
 26. Ciani O, Wilcher B, Blankart CR, et al. Health technology assessment 
of medical devices: a survey of non-European Union agencies. Int J 
Technol Assess Health Care 2015;31:154–65.
 27. Heneghan C, Aronson JK, Goldacre B, et al. Transvaginal mesh 
failure: lessons for regulation of implantable devices. BMJ 
2017;359.
 28. Sedrakyan A, Campbell B, Merino JG, et al. IDEAL-D: a rational 
framework for evaluating and regulating the use of medical devices. 
BMJ 2016;353.
 29. MDEpiNet. Vascular Implant Surveillance &Amp; Interventional 
Outcomes Network (VISION) CRN. Available: http:// mdepinet. org/ 
vision- crn/
 30. Beyond compliance. Available: www. beyondcompliance. org. uk
 31. CPRD. Clinical Practice Research Datalink. Available: www. cprd. com
 32. Sabah SA. Risk of heart failure in the first seven years following hip 
replacement using metal-on-metal versus alternative prostheses. 
Bone Joint J 2018;100-B:20–7.
 33. MDEpiNet. Available: http:// mdepinet. org/
 34. FDA. MDEpiNet: mission, objectives, and strategy. Available: https://
www. fda. gov/ MedicalDevices/ ScienceandResearch/ Epid emio logy 
Medi calD evices/ Medi calD evic eEpi demi olog yNet work MDEpiNet/ 
ucm296425. htm
 35. Wilkinson J, Crosbie A. A UK medical devices regulator’s perspective 
on registries. Biomed Tech 2016;61:233–7.
 36. Sedrakyan A, Campbell B, Graves S, et al. Surgical registries 
for advancing quality and device surveillance. The Lancet 
2016;388:1358–60.
 37. Glynn D, Campbell B, Marlow M, et al. How to improve the quality of 
evidence when new treatments are funded conditional on collecting 
evidence of effectiveness and safety. J Health Serv Res Policy 
2016;21:71–2.
 38. EUnetHTA Joint Action 3 Work Package 5—life cycle approach to 
improve evidence generation—REQueST® tool. Available: https://
www. eunethta. eu/ request- tool- and- its- vision- paper- are- now- 
available- for- public- consultation/
 39. Methodologic Principles in the Use of International Device Registry 
Data—IMDRF/RegistryWG/N42FINAL; 2017.
 40. Principles of international system of registries linked to other data 
sources and tools IMDRF/REGISTRYWG/N33 FINAL:2016; 2016.
 41. Washington Business Journal. One scary comparison: one night's 
hospital stay in the U.S. vs. rest of the world. Available: https://www. 
bizjournals. com/ washington/ blog/ 2014/ 04/ one- nights- hospital- stay- 
in- the- us- vs- rest. html
 42. NICE. The TURis system for transurethral resection of the prostate. 
Available: https://www. nice. org. uk/ guidance/ mtg23
copyright.
 o
n
 July 7, 2020 by guest. Protected by
http://sit.bmj.com/
BM
J Surg Interv Health Technologies: first published as 10.1136/bmjsit-2019-000022 on 4 September 2019. Downloaded from 
5Campbell B, et al. BMJ Surg Interv Health Technologies 2019;1:e000022. doi:10.1136/bmjsit-2019-000022
Open access
 43. Gov.UK. Reference costs guidance 2015–16. Available: https:/www. 
gov. uk/ government/ uploads/ system/ uploads/ attachment_ data/ file/ 
497127/ Reference_ costs_ guidance_ 2015- 16. pdf
 44. FDA. Requests for feedback and meetings for medical device 
submissions: the Q-Submission program, 2019. Available: https://
www. fda. gov/ downloads/ medicaldevices/ devi cere gula tion andg 
uidance/ guidancedocuments/ ucm311176. pdf
 45. FDA. Investigational device exemptions (IDEs) for early feasibility 
medical device clinical studies, including certain first in human 
(FIH) studies, 2013. Available: https://www. fda. gov/ downloads/ 
medicaldevices/ devi cere gula tion andg uidance/ guidancedocuments/ 
ucm279103
 46. FDA. Payor Communication Task Force. Available: https://www. fda. 
gov/ AboutFDA/ CentersOffices/ Offi ceof Medi calP rodu ctsa ndTo bacco/ 
CDRH/ CDRHInnovation/ ucm456149. htm
 47. Federal Register. Program for parallel review of medical devices, 
2016. Available: https://www. federalregister. gov/ documents/ 2016/ 
10/ 24/ 2016- 25659/ program- for- parallel- review- of- medical- devices
 48. NICE. Medtech Early Technical Assessment (META) Tool, 2017. 
Available: https:// meta. nice. org. uk/
 49. MaRS excite. Available: https://www. marsdd. com/ systems- change/ 
mars- excite/ mars- excite/
 50. Marcus HJ, Payne CJ, Hughes-Hallett A, et al. Regulatory approval 
of new medical devices: cross sectional study. BMJ 2016;253.
copyright.
 o
n
 July 7, 2020 by guest. Protected by
http://sit.bmj.com/
BM
J Surg Interv Health Technologies: first published as 10.1136/bmjsit-2019-000022 on 4 September 2019. Downloaded from 
